Salcaprozate sodium

A pharmaceutical excipient used to enhance drug absorption

Salcaprozate sodium
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Salcaprozate sodium (SNAC) is a pharmaceutical excipient used to enhance the absorption of certain drugs in the gastrointestinal tract. It is particularly noted for its role in improving the bioavailability of orally administered peptides and proteins, which are typically poorly absorbed when taken by mouth.

Mechanism of Action

Salcaprozate sodium functions as an absorption enhancer by temporarily altering the permeability of the intestinal epithelium. It interacts with the lipid bilayer of the cell membranes, facilitating the paracellular transport of large molecules that would otherwise be unable to pass through the tight junctions between epithelial cells. This mechanism allows for increased absorption of drugs that are otherwise limited by their size or hydrophilicity.

Applications

Salcaprozate sodium is used in the formulation of oral medications that require enhanced absorption. It is particularly useful in the development of oral peptide drugs, such as insulin, which are traditionally administered via injection due to poor oral bioavailability. By incorporating SNAC, pharmaceutical companies aim to create more convenient oral dosage forms that improve patient compliance and quality of life.

Pharmacokinetics

The pharmacokinetic profile of drugs formulated with salcaprozate sodium can vary significantly depending on the specific drug and formulation. SNAC itself is not absorbed into the systemic circulation in significant amounts, and its effects are localized to the gastrointestinal tract. The absorption enhancement effect is transient, allowing the intestinal barrier to return to its normal state after the drug has been absorbed.

Safety and Tolerability

Salcaprozate sodium is generally well-tolerated, with a safety profile that supports its use in pharmaceutical formulations. The temporary alteration of intestinal permeability is reversible, and studies have shown that SNAC does not cause long-term damage to the intestinal lining. However, as with any excipient, the safety of SNAC must be evaluated in the context of the specific drug formulation and patient population.

Development and Commercialization

Salcaprozate sodium has been developed and commercialized by several pharmaceutical companies as part of their efforts to create oral formulations of drugs that are traditionally administered via injection. The use of SNAC in drug development is subject to regulatory approval, and its inclusion in a formulation must be justified by demonstrating improved bioavailability and clinical benefit.

Related pages

• Pharmaceutical formulation
• Drug delivery
• Bioavailability
• Peptide therapeutics